Skip to main content
SpringerLink
Log in

β-Blockers could improve the 28-day and 3-year survival of patients with end-stage renal disease: a retrospective cohort study

  • Nephrology - Original Paper
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Background

Dialysis or non-dialysis end-stage renal disease (ESRD) patients are accompanied by cardiovascular disease (CVD) or hypertension. We aimed to study the effect of a common treatment for CVD, β-blockers, on the survival of ESRD patients, improving their prognosis from the perspective of drug therapy.

Methods

It was a retrospective cohort study using the Medical Information Mart for Intensive Care dataset. ESRD patients in the intensive care unit from June 2001 to October 2012 were included. We examined the effect of using versus not using β-blockers in the overall population and subgroups with the risk of 28-day and 3-year mortality through Cox proportional hazards models and Kaplan–Meier curves.

Results

A total of 1639 participants were included with 371 (22.64%) β-blockers users. There were 315 (19.22%) 28-day and 970 (59.18%) 3-year mortality events during follow-up. Using β-blockers in overall ESRD patients could reduce all-cause 28-day mortality [adjusted hazard ratio (HR) 0.450, 95% confidence interval (CI) 0.325–0.624] and 3-year mortality (adjusted HR 0.695, 95% CI 0.589–0.821). This result was consistent among subgroups (ESRD without hypertension: adjusted HR 0.412, 95% CI 0.289–0.588; with CVD: adjusted HR 0.478, 95% CI 0.321–0.711; without CVD: adjusted HR 0.448, 95% CI 0.248–0.810; with dialysis: adjusted HR 0.471, 95% CI 0.320–0.694) in 28-day mortality, and the 3-year mortality was consistent. In ESRD patients with hypertension and without dialysis subgroups, β-blockers had no effect on survival.

Conclusion

Using β-blockers could reduce the risk of 28-day and 3-year mortality in ESRD patients, including those with CVD. This study provided a reference for the treatment of β-blockers in patients with ESRD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Data Availability

The data that support the findings of this research are available from the corresponding author, upon reasonable request.

References

  1. Wark DM (2020) Hypnosis and end-stage renal disease: review and treatment. Am J Clin Hypn 63:36–48

    Article  PubMed  Google Scholar 

  2. United States Renal Data System. 2018 Annual data report: epidemiology of kidney disease in the United States. 2018. Accessed on Nov 28,2021. Available at https://www.usrds.org

  3. Johansen KL, Chertow GM, Foley RN, Gilbertson DT, Herzog CA, Ishani A et al (2021) US renal data system 2020 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis 77(4 Suppl 1):A7–A8

    Article  PubMed  PubMed Central  Google Scholar 

  4. Van Buren PN, Inrig JK (2016) Mechanisms and treatment of intradialytic hypertension. Blood Purif 41:188–193

    Article  PubMed  Google Scholar 

  5. Modi ZJ, Lu Y, Ji N, Kapke A, Selewski DT, Dietrich X et al (2019) Risk of cardiovascular disease and mortality in young adults with end-stage renal disease: an analysis of the US renal data system. JAMA Cardiol 4:353–362

    Article  PubMed  PubMed Central  Google Scholar 

  6. Sarnak MJ, Amann K, Bangalore S, Cavalcante JL, Zarbock A (2019) Chronic kidney disease and coronary artery disease. J Am Coll Cardiol 74:1823–1838

    Article  CAS  PubMed  Google Scholar 

  7. Sinha AD, Agarwal R (2019) Clinical pharmacology of antihypertensive therapy for the treatment of hypertension in CKD. Clin J Am Soc Nephrol 14:757–764

    Article  CAS  PubMed  Google Scholar 

  8. Lindholm LH, Ibsen H, Dahlöf B et al (2002) Cardiovascular morbidity and mortality in patients with diabetes in the Losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359:1004–1010

    Article  CAS  PubMed  Google Scholar 

  9. Roberts MA, Pilmore HL, Ierino FL, Badve SV, Cass A, Garg AX et al (2016) The beta-blocker to lower cardiovascular dialysis events (BLOCADE) Feasibility study: a randomized controlled trial. Am J Kidney Dis 67:902–911

    Article  CAS  PubMed  Google Scholar 

  10. Jin J, Guo X, Yu Q (2019) Effects of beta-blockers on cardiovascular events and mortality in dialysis patients: a systematic review and meta-analysis. Blood Purif 48:51–59

    Article  PubMed  Google Scholar 

  11. Zhou H, Sim JJ, Shi J, Shaw SF, Lee M-S, Neyer JR et al (2021) β-Blocker use and risk of mortality in heart failure patients initiating maintenance dialysis. Am J Kidney Dis 77:704–712

    Article  CAS  PubMed  Google Scholar 

  12. Johnson AE, Pollard TJ, Shen L, Lehman LH, Feng M, Ghassemi M et al (2016) MIMIC-III, a freely accessible critical care database. Sci Data. 3:160035

  13. Saeed M, Villarroel M, Reisner AT, Clifford G, Lehman LW, Moody G et al (2011) Multiparameter intelligent monitoring in intensive care II: a public-access intensive care unit database. Crit Care Med 39:952–960

    Article  PubMed  PubMed Central  Google Scholar 

  14. Assimon MM, Brookhart MA, Fine JP, Heiss G, Layton JB, Flythe JE (2018) A Comparative study of carvedilol versus metoprolol initiation and 1-year mortality among individuals receiving maintenance hemodialysis. Am J Kidney Dis 72:337–348

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Roberts MA, Pilmore HL, Ierino FL, Badve SV, Hawley CM et al (2016) The β-blocker to lower cardiovascular dialysis events (BLOCADE) feasibility study: a randomized controlled trial. Am J Kidney Dis 67:902–911

    Article  CAS  PubMed  Google Scholar 

  16. Bangalore S, Maron DJ, O’Brien SM, Fleg JL, Kretov EI, Briguori C et al (2020) Management of coronary disease in patients with advanced kidney disease. N Engl J Med 382:1608–1618

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Molnar AO, Petrcich W, Weir MA, Garg AX, Walsh M, Sood MM (2020) The association of beta-blocker use with mortality in elderly patients with congestive heart failure and advanced chronic kidney disease. Nephrol Dial Transplant 35:782–789

    Article  CAS  PubMed  Google Scholar 

  18. Wu PH, Lin YT, Kuo MC, Liu JS, Tsai YC, Chiu YW et al (2020) Beta-blocker dialyzability and the risk of mortality and cardiovascular events in patients undergoing hemodialysis. Nephrol Dial Transplant 35:1959–1965

    Article  CAS  PubMed  Google Scholar 

  19. Reboussin DM, Allen NB, Griswold ME, Guallar E, Hong Y, Lackland DT et al (2018) Systematic review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the american college of cardiology/american heart association task force on clinical practice guidelines. Circulation 138:e595–e616

    Article  PubMed  Google Scholar 

  20. Makar MS, Pun PH (2017) Sudden cardiac death among hemodialysis patients. Am J Kidney Dis 69:684–695

    Article  PubMed  PubMed Central  Google Scholar 

  21. Apel M, Maia VP, Zeidan M, Schinkoethe C, Wolf G, Reinhart K, Sakr Y (2013) End-stage renal disease and outcome in a surgical intensive care unit. Crit Care 17:R298

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Funding

This research received no funding.

Author information

Author notes

  1. Hui Dong and Lang Zhou have contributed equally to this work and are first co-authors.

Authors and Affiliations

  1. Department of Intensive Care Unit, Wuhan Third Hospital, Wuhan, 430000, Hubei, People’s Republic of China

    Hui Dong, Luyu Yang, Huizhi Lu, Song Cao, Huimin Song & Shouzhi Fu

  2. Department of Interventional Medicine, Wuhan Third Hospital, Wuhan, 430000, Hubei, People’s Republic of China

    Lang Zhou

Authors
  1. Hui Dong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lang Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Luyu Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Huizhi Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Song Cao
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Huimin Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Shouzhi Fu
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

HD, LZ and SZF designed the study and wrote the manuscript. LYY, HZL, SC and HMS collected, analyzed and interpreted the data. SZF critically reviewed, edited and approved the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Shouzhi Fu.

Ethics declarations

Conflict of interest

The authors have declared that no conflict of interest exists.

Ethical approval

MIMIC-III is a large, freely available database comprising de-identified health-related data, this study was exempt from the Institutional Review Board approval at our hospital. All methods were carried out in accordance with relevant guidelines and regulations (declaration of Helsinki).

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 60 KB)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dong, H., Zhou, L., Yang, L. et al. β-Blockers could improve the 28-day and 3-year survival of patients with end-stage renal disease: a retrospective cohort study. Int Urol Nephrol 55, 1597–1607 (2023). https://doi.org/10.1007/s11255-023-03466-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-023-03466-8

Keywords

Search

Navigation